Thu, August 11, 2011
Wed, August 10, 2011
Tue, August 9, 2011
Mon, August 8, 2011
Sun, August 7, 2011
Sat, August 6, 2011
Fri, August 5, 2011
Thu, August 4, 2011
Wed, August 3, 2011
Tue, August 2, 2011
Mon, August 1, 2011
Sun, July 31, 2011
Fri, July 29, 2011
Thu, July 28, 2011
Wed, July 27, 2011
[ Wed, Jul 27th 2011 ]: Market Wire
00 AM EDT
Tue, July 26, 2011
Mon, July 25, 2011
Sat, July 23, 2011
Fri, July 22, 2011
Thu, July 21, 2011
Wed, July 20, 2011
[ Wed, Jul 20th 2011 ]: Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ]: Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ]: Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011

Geron Announces Conference Call to Discuss Second Quarter Financial Results and Highlights


//health-fitness.news-articles.net/content/2011/ .. nd-quarter-financial-results-and-highlights.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


MENLO PARK, Calif.--([ BUSINESS WIRE ])--Geron Corporation (Nasdaq:GERN) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, July 28, 2011, after the closing of the equity market. David L. Greenwood, Gerona™s President and Chief Executive Officer, will host a conference call for analysts and investors on Friday, July 29, 2011 at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time.

Participants can access the conference call live via telephone by dialing 800-591-6944 (U.S.); 617-614-4910 (international). The passcode is 38893153. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at [ http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=67323&eventID=4162511 ]. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through August 30, 2011.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury. For more information, visit [ www.geron.com ].


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear